Saturday 17 October 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.21
0.32
−2.37%
Follow IART
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (0.70%) | (38.64%) | (39.90%) | (38.71%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 5 | 5 | 5 | |
| (0.20%) | (13.00%) | (13.52%) | (12.85%) | ||
ROIC |
1.58% | (11.20%) | (11.87%) | (11.73%) | |
Return on Tangible Assets |
(0.55%) | (38.98%) | (44.99%) | (40.70%) | |
Average Days of Receivables |
59.19 | 58.69 | 62.24 | 58.24 | |
Free Cash Flow per Share |
0.33 | 0.05 | (0.40) | (0.06) | |
Free Cash Flow |
25.80 | 4.08 | (31.05) | (4.51) | |
Capital Expenditures |
(59.52) | (67.36) | (81.44) | (93.82) | |
| Other line items | |||||
Cash ROIC |
0.82% | 0.13% | (0.99%) | (0.15%) | |
Accounts Receivable Turnover |
5.97 | 6.36 | 5.93 | 6.44 | |
Accounts Payable Turnover |
8.93 | 8.82 | 9.02 | 9.22 | |
Inventory Turnover |
1.64 | 1.68 | 1.74 | 1.69 | |
Average Days of Payables |
38.52 | 40.62 | 43.48 | 43.02 | |
Days of Inventory on Hand |
229.33 | 228.62 | 223.80 | 227.96 | |
Tax Rate |
39.46 | (0.07) | (0.08) | (0.09) | |
Research and Development Expense of Revenue |
5.77% | 5.94% | 6.05% | 6.41% | |
Selling, General and Administrative Expense of Revenue |
41.82% | 42.35% | 42.79% | 43.15% | |
Share Based Compensation of Revenue |
1.36% | 1.33% | 1.14% | 1.21% | |
Interest Coverage |
0.71 | (5.19) | (5.72) | (5.89) | |
Operating CF/Net income |
(11.78) | (0.14) | (0.10) | (0.18) | |
Depreciation/Fixed assets |
0.35 | 0.35 | 0.35 | 0.36 | |
Capex/Depreciation |
(0.38) | (0.43) | (0.52) | (0.60) | |
Revenue per Share |
21.32 | 21.37 | 21.33 | 21.41 | |
Operating CF per Share |
1.10 | 0.93 | 0.66 | 1.16 | |
Capex per Share |
(0.77) | (0.88) | (1.06) | (1.22) | |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.06 |
Columns are period end dates